Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1999 Jun;54(6):482–487. doi: 10.1136/thx.54.6.482

Randomised trial of an inhaled β2 agonist, inhaled corticosteroid and their combination in the treatment of asthma

R Hancox 1, J Cowan 1, E Flannery 1, G Herbison 1, C McLachlan 1, C Wong 1, D Taylor 1
PMCID: PMC1745487  PMID: 10335000

Abstract

BACKGROUND—Although many asthmatic patients are treated with a combination of β2 agonist and corticosteroid inhalers, the clinical effects of combining the drugs are unknown. Studies on the early asthmatic response to allergen suggest that β2 agonists may reduce the benefit of inhaled corticosteroids. A study of the effects of combining the drugs on asthma control was undertaken.
METHODS—Sixty one subjects with mild to moderate asthma were randomised to a double blind crossover comparison of inhaled budesonide (200-400 µg twice daily), terbutaline (500-1000 µg four times daily), combined treatment, and placebo. Each treatment was given for six weeks following a four week washout period. Ipratropium was used for symptom relief. Treatments were ranked from worst (1) to best (4) based on need for oral steroid, mean morning peak flow, nocturnal awakening, ipratropium use, and asthma symptoms. Lung function and bronchial hyperresponsiveness were measured before and after each treatment.
RESULTS—Evaluable data for all four treatments were obtained from 47 subjects. The mean rank of each treatment was: placebo = 2.05; terbutaline = 2.13; budesonide = 2.48; combined treatment = 3.34.Combined treatment was ranked significantly better than any other treatment (p<0.01). Mean (95% CI) morning and evening peak flows were 14 (5 to 23) and 24 (15 to 34) l/min higher, respectively, during combined treatment than during budesonide, and 27 (17 to 37) and 15 (7 to 23) l/min higher than during terbutaline. Asthma symptoms tended to be least frequent during combined treatment but were not significantly different from budesonide alone. There was no significant difference between combined treatment and budesonide alone for lung function and bronchial hyperresponsiveness.
CONCLUSIONS—In this group of mild to moderate asthmatic subjects the combination of β2 agonist and corticosteroid gave better asthma control than either treatment alone. There was no evidence that regular β2 agonist treatment impaired the beneficial effect of inhaled corticosteroid.



Full Text

The Full Text of this article is available as a PDF (146.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adcock I. M., Stevens D. A., Barnes P. J. Interactions of glucocorticoids and beta 2-agonists. Eur Respir J. 1996 Jan;9(1):160–168. doi: 10.1183/09031936.96.09010160. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J., O'Connor B. J. Use of a fixed combination beta 2-agonist and steroid dry powder inhaler in asthma. Am J Respir Crit Care Med. 1995 Apr;151(4):1053–1057. doi: 10.1164/ajrccm.151.4.7697230. [DOI] [PubMed] [Google Scholar]
  3. Bennati D., Piacentini G. L., Peroni D. G., Sette L., Testi R., Boner A. L. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. J Asthma. 1989;26(6):359–364. doi: 10.3109/02770908909073279. [DOI] [PubMed] [Google Scholar]
  4. Chai H., Farr R. S., Froehlich L. A., Mathison D. A., McLean J. A., Rosenthal R. R., Sheffer A. L., Spector S. L., Townley R. G. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol. 1975 Oct;56(4):323–327. doi: 10.1016/0091-6749(75)90107-4. [DOI] [PubMed] [Google Scholar]
  5. Cockcroft D. W., Swystun V. A., Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1485–1489. doi: 10.1164/ajrccm.152.5.7582281. [DOI] [PubMed] [Google Scholar]
  6. Drazen J. M., Israel E., Boushey H. A., Chinchilli V. M., Fahy J. V., Fish J. E., Lazarus S. C., Lemanske R. F., Martin R. J., Peters S. P. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996 Sep 19;335(12):841–847. doi: 10.1056/NEJM199609193351202. [DOI] [PubMed] [Google Scholar]
  7. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  8. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  9. Peters M. J., Adcock I. M., Brown C. R., Barnes P. J. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur J Pharmacol. 1995 Apr 28;289(2):275–281. doi: 10.1016/0922-4106(95)90104-3. [DOI] [PubMed] [Google Scholar]
  10. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  11. Sears M. R., Taylor D. R. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994 Oct;11(4):259–283. doi: 10.2165/00002018-199411040-00005. [DOI] [PubMed] [Google Scholar]
  12. Taylor D. R., Sears M. R., Herbison G. P., Flannery E. M., Print C. G., Lake D. C., Yates D. M., Lucas M. K., Li Q. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax. 1993 Feb;48(2):134–138. doi: 10.1136/thx.48.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taylor D. R., Town G. I., Herbison G. P., Boothman-Burrell D., Flannery E. M., Hancox B., Harré E., Laubscher K., Linscott V., Ramsay C. M. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax. 1998 Sep;53(9):744–752. doi: 10.1136/thx.53.9.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wilding P. J., Clark M. M., Oborne J., Bennett J. A., Tattersfield A. E. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax. 1996 Oct;51(10):989–992. doi: 10.1136/thx.51.10.989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wong C. S., Wahedna I., Pavord I. D., Tattersfield A. E. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1268–1273. doi: 10.1164/ajrccm.150.5.7952551. [DOI] [PubMed] [Google Scholar]
  16. Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]
  17. Yan K., Salome C., Woolcock A. J. Rapid method for measurement of bronchial responsiveness. Thorax. 1983 Oct;38(10):760–765. doi: 10.1136/thx.38.10.760. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES